Table 1 |
|||
|
Results of univariate and multivariate models assessing HR of exposures on lymphoma development in SLE patients |
|||
|
Variable |
Univariate HR (95% CI) |
Partially adjusted model (95% CI) |
Multivarate HR (95% CI) |
|
|
|||
|
Cyclophosphamide (CY) ever |
1.73 (0.90 to 3.33) |
1.99 (1.00 to 3.96) |
1.95 (0.61 to 6.22) |
|
Cumulative CY >6 g |
1.51 (0.63 to 3.62) |
- |
0.79 (0.18 to 3.54) |
|
Azathioprine (AZA) ever |
0.82 (0.45 to 1.52) |
- |
1.28 (0.53 to 3.07) |
|
Cumulative AZA >36.5 g |
0.49 (0.19 to 1.25) |
- |
0.46 (0.14 to 1.54) |
|
Methotrexate ever used |
0.99 (0.45 to 2.16) |
- |
0.79 (0.30 to 2.05) |
|
Mycophenolate ever used |
1.38 (0.58 to 3.29) |
- |
1.74 (0.70 to 4.34) |
|
Antimalarials ever used |
1.47 (0.80 to 2.69) |
- |
1.39 (0.69 to 2.78) |
|
Glucocorticosteroids (GC) ever |
1.39 (0.75 to 2.56) |
- |
1.03 (0.40 to 2.64) |
|
Cumulative GCa >3.5 g |
1.27 (0.75 to 2.17) |
- |
1.59 (0.69 to 3.67) |
|
Disease activity (second tertile)b |
1.00 (0.55 to 1.82) |
- |
1.10(0.56 to 2.14) |
|
Disease activity (third tertile) |
0.43 (0.22 to 0.84) |
0.49 (0.27 to 0.90) |
0.52 (0.24 to 1.12) |
|
Outside North America |
1.04 (0.53 to 2.05) |
- |
1.06 (0.45 to 2.50) |
|
Male |
2.47 (1.24 to 4.92) |
- |
2.21 (1.05 to 4.66) |
|
Age |
1.05 (1.03 to 1.07) |
1.04 (1.03 to 1.06) |
1.05 (1.03 to 1.07) |
|
White race/ethnicity |
0.97 (0.55 to 1.71) |
- |
0.86 (0.46 to 1.59) |
|
Calendar year |
1.01 (0.98 to 1.05) |
- |
0.98 (0.94 to 1.02) |
|
Sjögren's syndrome |
1.29 (0.66 to 2.54) |
- |
1.21 (0.53 to 2.78) |
|
|
|||
|
aSystemic glucocorticosteroids, considered in prednisone equivalent doses. bMean adjusted SLE Disease Activity-2K (SLEDAI-2K). |
|||
|
Clarke et al. Arthritis Research & Therapy 2012 14(Suppl 3):A16 doi:10.1186/ar3950 |
|||